Job Trends
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Looking for a research and development job? Check out the BioSpace list of 12 companies hiring life sciences professionals like you.
Career Advice
If workloads aren’t adjusted as needed, the company’s priorities are already compromised. Executive coach Angela Justice explores what happens when goals move forward without removing unnecessary work and what to do about it.
THE LATEST
Phase III trial validates the benefit of veliparib for patients without a BRCA mutation
Eosera gives a sneak peek into new products and announces the move to a bigger location due to rapid growth.
Neos Therapeutics, Inc. announced that Jerry McLaughlin, chief executive officer, will present a company overview at the upcoming Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 2, 2019 at 9:30 a.m. ET in New York, NY.
Current Chief Executive Officer Albert Bourla will succeed Read as chairman on Jan. 1, 2020 and will continue to serve as CEO.
PARP inhibitors will be taking center stage at the European Society of Medical Oncology Congress as rival drugmakers aim to show off data that supports broader use of the drug in treating various cancers.
New clinical data shows that Eli Lilly’s investigational oncology drug pegilodecakin, in combination with a checkpoint inhibitor, could be a potential new treatment for patients with non-small cell lung cancer and kidney cancer.
It was a moderately busy week for clinical trial news. Here’s a look.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
APEX Biologix, a nationally recognized leader in manufacturing and distributing cutting-edge biologic supplies will now have access to an exciting new product.
Scientists have known for decades that electrical stimulation promotes healing of chronic wounds, such as diabetic ulcers and bedsores, but how it happens has been a mystery